Bulk Bag Discharge in Pharmaceutical Production

Bulk bag discharge in a pharmaceutical plant is a containment problem wearing the clothes of a handling problem.

The mechanics are the same as anywhere: the bag deforms, the powder bridges, the spout has to be opened. What changes is that the opening of the spout is an exposure event that has to be demonstrated, not merely managed, and that every contact surface has to be cleanable in a way that can be validated.

A transfer in which the bag is emptied completely and the operator is never exposed to the product, with evidence to show it.

The measurable result is an exposure figure from a standardised test, under the conditions the plant will actually run, including the disconnection and the cleaning that follow.

Partial discharge handled deliberately or excluded deliberately. Taking part of a bag and closing it again is the hardest case for containment, because the connection has to be broken with product still in the liner, and plants that need it should specify it rather than discover it.

In plastics compounding the same station is judged on static: a non-conductive component anywhere in the path holds the charge the pellets brought with them.

The bag is lifted into the frame and the spout is connected into a contained interface before anything is opened.

Where the compound requires it, that interface is a split butterfly valve or a continuous liner system rather than a clamp and a seal. Both keep the product path closed through the connection, the discharge and the disconnection.

Massaging or vibration works the powder down as in any other plant, but the devices have to be cleanable and must not create a route for product to escape the containment.

The liner is removed at the end through a procedure designed for it, which in a continuous liner system means crimping and cutting within the contained zone rather than opening it in the room.

Explosion protection is settled alongside the containment rather than after it. Lactose, starch and most granulations are explosible, and the station is a vessel holding a dust cloud by design. Inerting fits a contained station well, since the enclosure already holds an atmosphere, and it avoids the question of a suppressant touching the product.

• Closed interface before opening, always.
• Containment maintained through disconnection, not only during flow.
• Cleaning validated on the interface, not only on the vessel.
• Partial discharge specified or excluded explicitly, since it is the hardest containment case.
• Explosion concept settled with the containment concept, with inerting often the natural fit.
• Massaging devices chosen so they are cleanable and do not breach the containment.

• Containment band of the compound, which sets the interface type and the measured performance required.
• Cleaning method and whether the interface can be cleaned in place or has to be removed.
• Flow behaviour, which decides the massaging requirement independently of the containment.
• Batch size and whether partial discharge is needed, which complicates containment considerably.
• Qualification burden: every contact part is part of the validated system.
• Explosion characteristics, since many pharmaceutical powders are explosible and inerting may be required.
• Partial discharge requirement, which complicates the interface considerably.